Rocket


Overview
Financials
News + Filings
Key Docs
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation

Apellis Pharmaceuticals, Inc. (APLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
10/10/2023 144 Form 144 - Report of proposed sale of securities:
10/05/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE ® in the Third Quarter of 2023"
08/22/2023 8-K Other Events  Interactive Data
08/09/2023 4 Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 12,000 shares @ $23.66, valued at $283.9k
Exercised 18,500 options to buy @ $2.67, valued at $49.4k
08/08/2023 144 Form 144 - Report of proposed sale of securities:
07/31/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/31/2023 8-K Quarterly results
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/18/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/18/2023 4 Machiels Alec (Director) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 1,250 shares @ $64.79, valued at $81k
Exercised 1,250 options to buy @ $2.67, valued at $3.3k
07/17/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/11/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/10/2023 144 Form 144 - Report of proposed sale of securities:
07/07/2023 SC 13G/A BlackRock Inc. reports a 4.9% stake in Apellis Pharmaceuticals Inc
07/06/2023 4 Watson David O. (General Counsel) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 8,510 shares @ $89.98, valued at $765.7k
07/06/2023 4 Sullivan Timothy Eugene (CFO) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 3,192 shares @ $89.4109, valued at $285.4k
Sold 3,287 shares @ $90.4165, valued at $297.2k
Sold 300 shares @ $91.0983, valued at $27.3k
Exercised 6,779 options to buy @ $10.03, valued at $68k
07/03/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/29/2023 4 Watson David O. (General Counsel) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Gifted 12,750 shares @ $0
Gifted 12,750 shares @ $0
06/09/2023 4 Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 12,000 shares @ $91.35, valued at $1.1M
Exercised 18,500 options to buy @ $2.67, valued at $49.4k
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/06/2023 4 Sullivan Timothy Eugene (CFO) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 1,600 shares @ $90.6044, valued at $145k
Sold 30,609 shares @ $87.7886, valued at $2.7M
Sold 7,064 shares @ $88.3649, valued at $624.2k
Sold 30,506 shares @ $89.8259, valued at $2.7M
Exercised 69,779 options to buy @ $10.03, valued at $699.9k
06/02/2023 4 Lewis Karen (Chief People Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 5,000 shares @ $86, valued at $430k
Exercised 5,000 options to buy @ $34.11, valued at $170.6k
06/01/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 4 Francois Cedric (CEO) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Gifted 20,000 shares @ $0
Gifted 20,000 shares @ $0
05/18/2023 4 Machiels Alec (Director) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 1,250 shares @ $88.66, valued at $110.8k
Exercised 1,250 options to buy @ $2.67, valued at $3.3k
05/18/2023 4 Francois Cedric (CEO) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns: Sold 934 shares @ $83.1711, valued at $77.7k
Sold 1,800 shares @ $83.845, valued at $150.9k
Sold 14,611 shares @ $85.0089, valued at $1.2M
Sold 3,007 shares @ $85.9012, valued at $258.3k
Sold 7,528 shares @ $87.0163, valued at $655.1k
Sold 2,120 shares @ $87.6739, valued at $185.9k
Exercised 30,000 options to buy @ $2.67, valued at $80.1k
Exercised 20,000 options to buy @ $2.67, valued at $53.4k
05/17/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 144 Form 144 - Report of proposed sale of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy